Innovent Biologics has received approval from China's National Medical Products Administration (NMPA) for mazdutide for chronic weight management in adults with obesity or overweight 1 4 . Mazdutide, developed in partnership with Eli Lilly, is the first dual glucagon/GLP-1 receptor agonist (GCG/GLP-1 RA) approved globally, representing a new drug class in obesity treatment 4 . Mazdutide is an oxyntomodulin analogue, showing not only strong weight loss and glucose-lowering effects but also improvements in waist circumference, blood lipids, blood pressure, uric acid levels, liver enzymes, and insulin sensitivity 2 . The approval highlights China's emergence as a source of innovative obesity treatments and reinforces Innovent's position in the metabolic disease market 5 . Mazdutide's clinical program includes seven ongoing Phase 3 trials, and it has submitted two NDAs to the NMPA: for long-term weight management and for glycemic control in type 2 diabetes 2 3 . ...
- Get link
- X
- Other Apps